The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II of sunitinib plus nivolumab in extraskeletal myxoid chondrosarcoma: Results from the GEIS, ISG, and UCL IMMUNOSARC II Study.
 
Nadia Hindi
Honoraria - Deciphera; PharmaMar
Consulting or Advisory Role - Deciphera; PharmaMar
Research Funding - Abbisko Therapeutics (Inst); Adaptimmune (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Pfizer (Inst); CEBIOTEX (Inst); Cogent Biosciences (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim Spain; Deciphera; PharmaMar
 
Emanuela Palmerini
Consulting or Advisory Role - Deciphera pharmaceuticals, llc cf; SynOX
 
Irene Carrasco-Garcia
Honoraria - PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Cogent Medicine (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Enrique Gonzalezbilla
Consulting or Advisory Role - AstraZeneca; Bayer; Janssen Oncology
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Pfizer; Roche; Sanofi
 
Claudia Valverde Morales
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Deciphera; PharmaMar; Philogen
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Sandra Strauss
Consulting or Advisory Role - Boehringer Ingelheim; Ceridwen Oncology; GlaxoSmithKline; InhibRx; Tessallate Bio
Speakers' Bureau - Boehringer Ingelheim
Travel, Accommodations, Expenses - Adaptimmune
 
Toni Ibrahim
No Relationships to Disclose
 
Ana Sebio
Consulting or Advisory Role - Boehringer Ingelheim; Deciphera; GlaxoSmithKline; PharmaMar
Travel, Accommodations, Expenses - CEBIOTEX; Deciphera; Merck; PharmaMar; Roche
 
Robert Díaz-Beveridge
No Relationships to Disclose
 
Javier Martínez-Trufero
Consulting or Advisory Role - Boehringer Ingelheim Spain; Deciphera; Eisai; GlaxoSmithKline; PharmaMar
Research Funding - Ayala Pharmaceuticals (Inst); BionTech (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Kariopharm Therapeutics (Inst); Lilly (Inst); PharmaMar (Inst); Syneos Health (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Merck; PharmaMar; PharmaMar; Roche
 
Silvia Stacchiotti
Honoraria - Boehringer Ingelheim; Gentili; GlaxoSmithKline; PharmaMar; Servier
Consulting or Advisory Role - Agenus; Bayer; Boehringer Ingelheim; Daiichi Sankyo; deciphera; GlaxoSmithKline; Ikena Oncology; Ipsen; NEC OncoImmunity AS; Pharmaessentia; Regeneron; SERVIER
Research Funding - Abbisko Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Paola Collini
No Relationships to Disclose
 
Roberto Tirabosco
No Relationships to Disclose
 
Rafael Ramos
No Relationships to Disclose
 
Antonio Gutierrez
No Relationships to Disclose
 
David Moura
Honoraria - Tecnofarma
Research Funding - PharmaMar (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Bayer; Biosplice; Pfizer; PharmaMar
 
Javier Martin Broto
Leadership - Sarcoma Research Solutions SL
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar